Marshall Wace North America L.P. - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 228 filers reported holding SAGE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.20 and the average weighting 0.1%.

Quarter-by-quarter ownership
Marshall Wace North America L.P. ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q3 2021$9,484,000
-42.8%
214,034
-26.7%
0.04%
-42.9%
Q2 2021$16,588,000
-52.0%
291,989
-36.8%
0.07%
-51.4%
Q1 2021$34,558,000
-44.6%
461,701
-36.0%
0.14%
-49.3%
Q4 2020$62,383,000
+141.9%
721,108
+70.9%
0.28%
+72.1%
Q3 2020$25,789,000
+9381.2%
421,939
+4349.9%
0.16%
+8150.0%
Q1 2020$272,000
-98.8%
9,482
-94.3%
0.00%
-98.5%
Q3 2019$23,437,000
+1.4%
167,060
+32.4%
0.13%
-7.0%
Q2 2019$23,109,000
-86.6%
126,217
-88.3%
0.14%
-76.5%
Q1 2019$171,904,000
+268.7%
1,080,816
+122.1%
0.61%
+35.0%
Q4 2018$46,621,000
-66.3%
486,704
-50.2%
0.45%
-5.1%
Q3 2018$138,184,000
+67.3%
978,296
+85.4%
0.48%
+1.9%
Q2 2018$82,588,000
-18.9%
527,616
-16.5%
0.47%
-8.6%
Q1 2018$101,812,000
-3.0%
632,100
-0.8%
0.51%
-12.1%
Q4 2017$104,923,000
+2870.6%
637,017
+1018.3%
0.58%
+2536.4%
Q3 2017$3,532,000
-87.1%
56,961
-83.4%
0.02%
-89.0%
Q2 2017$27,379,000
-22.9%
342,238
-31.5%
0.20%
-28.6%
Q1 2017$35,493,000499,9050.28%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q3 2021
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 99,306$14,027,0005.76%
Casdin Capital, LLC 312,000$44,070,0005.36%
Palo Alto Investors LP 840,372$118,703,0004.80%
BB BIOTECH AG 1,071,373$151,331,0004.00%
TRV GP II, LLC 37,362$5,277,0003.10%
Eversept Partners, LP 43,621$6,161,4662.70%
RA Capital Management 350,933$49,569,0002.65%
Eventide Asset Management 494,000$69,778,0002.56%
OAK RIDGE INVESTMENTS LLC 241,099$34,055,0001.88%
SUFFOLK CAPITAL MANAGEMENT LLC 93,000$13,136,0001.87%
View complete list of SAGE THERAPEUTICS INC shareholders